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Microglia-mediated inflammation is an important step in the progression of
cerebral ischemia/reperfusion injury and the associated production of receptors of
immunomoudulation, including Toll-like receptors (TLRs). Peroxiredoxin 6 (Prdx6)
has been demonstrated as the endogenous antioxidant protein for its peroxidase
properties. However, the role of the independent phospholipase A2 (iPLA2) activity
of Prdx6 in stroke has not been well studied. In this study, we evaluated whether
blocking the calcium-iPLA2 activity of Prdx6 using siRNA and inhibitors (1-hexadecyl-
3-(trifluoroethgl)-sn-glycerol-2 phosphomethanol, MJ33) would have a critical effect on
inflammatory brain damage. We conducted oxygen-glucose deprivation (OGD)/recovery
(R) in vitro and middle cerebral artery occlusion (MCAO) in vivo in a microglia/neuron
co-culture system and in rats. In vitro, we found that Prdx6-iPLA2 activity was
associated with the secretion of neurotoxic inflammatory mediators interleukin1β (IL-1β),
interleukin-17 (IL-17) and interleukin-23 (IL-23) and elevated expression of Toll-like
receptor 2/4 (TLR2/4), leading to the formation of nuclear factor-kappa B (NF-κB),
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in microglial
cells. In vivo, combined treatment with Prdx6-iPLA2 activity inhibitor MJ33 showed a
greater diminution in neurologic deficits, cerebral infarction, brain water content and
inflammatory molecules than Prdx6-siRNA treatment alone. Our findings provide new
insight into Prdx6-iPLA2 function in the brain. Inhibition of Prdx6-iPLA2 activity by gene
therapy and/or pharmacology may constitute a promising new therapeutic approach to
the treatment of stroke.
Keywords: Prdx6-iPLA2 activity, cerebral ischemia/reperfusion, OGD/R, microglia/neuron co-culture system,
MJ33
INTRODUCTION
Despite the complex pathogenesis of ischemic stroke, emerging evidence suggests that
inflammation is an important step in the primary and secondary progression of cerebral
ischemia/reperfusion injury (Shichita et al., 2012a,b; Kuang et al., 2014; Yu et al., 2015). Microglia in
the brain plays a prominent role in initiating, sustaining and resolving post-ischemic inflammation
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(Chen et al., 2011; Benakis et al., 2014). It has previously been
recognized that inhibiting the activation of immunomoudulation
receptors, including Toll-like receptors (TLRs) caused by
microglial phagocytosis could prevent inflammatory neuronal
death (Neher et al., 2011; Kuang et al., 2014). Among the
TLRs, TLR2 and TLR4 are mainly expressed in the microglia
of the brain and have been found to be more important than
others in the immune response of the microglia (Wang et al.,
2013; Lv et al., 2016). Therefore, the mechanisms that underlie
microglia-neuron crosstalk are under extensive investigation for
the development of innovative neuroprotective therapies for
ischemic stroke.
Peroxiredoxin 6 (Prdx6) is the uniquely 1-Cys member of the
peroxiredoxin family with both GSH peroxidase and calcium-
independent phospholipase A2 (iPLA2) activities (Manevich and
Fisher, 2005). Although the GSH peroxidase activity of Prdx6 has
been widely studied in cell and animal models for its antioxidant
function, the function of the iPLA2 activity of Prdx6 remains
unclear. With loss- and gain-of-function mutations of Prdx6,
Kim et al. (2011) found that the restoration of Prdx6 without
iPLA2-mutant resulted in dramatic recovery of tumor necrosis
factor-induced apoptosis. Blocking Prdx6-iPLA2 activity by
its specific inhibitor 1-hexadecyl-3-(trifluoroethgl)-sn-glycerol-
2 phosphomethanol (MJ33) could significantly protect the
lung against damage from hyperoxia (Benipal et al., 2015).
Recently, Prdx6-iPLA2 activity has been reported as giving off
potent proinflammatory signals (Garcia-Bonilla and Iadecola,
2012; Shichita et al., 2012a,b). In human bronchial epithelial
cells (BEAS2B), the production of interleukin-1β (IL-1β) was
dependent on the iPLA2 activity of Prdx6 (Kim et al., 2011). Lee
et al. (2013) reported that Prdx6-iPLA2 activity was associated
with lung inflammation through activation of NADPH oxidase
(NOX2). In primary cultured astrocytes, iPLA2 activity of
Prdx6 induced astrocytic activation followed by increased
proinflammatory cytokines (tumor necrosis factor-α (TNF-α)
and IL-1β (Yun et al., 2015). All of these results strongly
suggest that the iPLA2 activity of Prdx6 may be involved in
the proinflammatory stimuli. However, until now, no study has
described the iPLA2 activity of the Prdx6 function in microglia-
mediated neuroinflammation and cerebral ischemia/reperfusion.
Based on previous research, we hypothesized that the
iPLA2 activity of Prdx6 has a critical role in cerebral
ischemia/reperfusion inflammatory injury. To explore the
molecular mechanism that underlines the critical effect
of Prdx6-iPLA2 activity, we conducted oxygen-glucose
deprivation/recovery (OGD/R) in vitro and middle cerebral
artery occlusion (MCAO) in vivo, in a microgila/neuron
co-culture system and in rats, respectively. siRNA and inhibitors
(MJ33) were used to inhibit Prdx6-iPLA2 enzymatic activity.
MATERIALS AND METHODS
Rat Primary Microglia/Neuron Co-Culture
System
Microglia and neurons were derived from 1-day-old Sprague-
Dawley rats. All experimental protocols were approved by the
Institutional Animal Care and Use Committee of Chongqing
Medical University, China. All efforts were made to minimize
suffering. Microglia-enriched cells were obtained by the method
of Suzumura et al. (1987). After maintenance of mixed glial
cultures for 9–12 days, microglial cells were separated by shaking
flasks for 1 h using a rotary shaker at 200 rpm. The isolated
cells were grown in DMEM/F12 supplemented with 10% FBS
and 1% penicillin/streptomycin. When the microglia’s growth
density reached 55%–60%, cortex neuron-enriched cultures were
obtained according to our previously published methods (Chen
et al., 2016; Li et al., 2016). The purity of the primary neuron
cultures was over 90%, as determined by neuron-specific marker
NeuN.
The rat primary microglia/neuron co-culture system was
performed as described previously with some changes (Correa
et al., 2013; Bi et al., 2014). Briefly, a Transwell co-culture
system utilized the non-contact Transwell inserts. Then the
primary microglia and neurons were co-cultured for a period of
24 h, sharing the same culture medium containing 2% B27 and
1% penicillin/streptomycin through a 0.4-µm transmembrane
that prevented cell migration but allowed small molecule
exchange.
Oxygen Glucose Deprivation and
Regeneration (OGD/R) and Groups
To simulate ischemic conditions, cultures were exposed to
OGD/R as we previously described (Chen et al., 2016; Li
et al., 2016). The medium was replaced by Neurobasal media
without glucose and the cells were placed in an incubator
with 1% O2, 94% N2 and 5% CO2 concentration. After a 6 h
OGD, reoxygenation was carried out by transferring the cells
to the normal cell culture incubator for 24 h. The co-culture
systems were divided into five groups: (1) control group
(Control): microglia without any treatment; (2) OGD/R group
(OGD/R); (3) scramble group (Scramble): microglia treated with
a scramble of siRNA and subjected to OGD/R; (4) Prdx6-
iPLA2 activity siRNA group (Prdx6-iPLA2 siRNA): microglia
transfected with Prdx6-iPLA2 siRNA and subjected to OGD/R;
and (5) MJ33 group (MJ33): microglia given MJ33 treatment
(50 µmol/L) and subjected to OGD/R.
Prdx6-iPLA2 siRNA
Lentivirus was supplied by Neuron Biotech (Shanghai, China). In
order to create siRNA in the iPLA2 activity of Prdx6, we knocked
down Prdx6 with lentivirus (NCBI accession no. NM_053576.2
→ NP-446028.1; shRNA, 5′-ACAGCCCGTGTGGTATTCAT-
3′). At the same time, reintroduction of over-expressed
Prdx6 without iPLA2 activity was performed by Ser32 gene
mutation into the knockdown cells. The iPLA2 assay kit (Xinyu
Biological Technology Co, Shanghai, China) and GSH assay kit
(Nanjin Jiancheng Bioengineering Institute, Nanjing, China) was
used to detect the lentivirus interference efficiency by measuring
the iPLA2 activity and GSH activity of Prdx6.
MTS Assay
Neuron viability was measured by an MTS assay kit (Nanjin
Jiancheng Bioengineering Institute, Nanjing, China) to detect
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any remaining dehydrogenase activity in living cells. After the
co-culture system was treated with OGD/R, a total of 10 uL
MTS was directly added to the neuron, then incubated for 2 h to
allowMTS to metabolize to formazan. The result was analyzed at
490 nmusing amicroplate reader (Bio-Rad). The neuron viability
was expressed as relative percentage compared with control cells.
Number of experiments: 9.
Lactate Dehydrogenase (LDH) Assay
The release of Lactate dehydrogenase (LDH) by microglia was
measured using the LDH assay kit according to manufacturer’s
instructions (Nanjin Jiancheng Bioengineering Institute,
Nanjing, China). Following treatment, the medium of the cell
co-culture system from each group was collected and transferred
to new 96-well plates, then mixed with the reaction solution
provided in the kit. The optical density was measured at 450 nm
using a microplate reader (Bio-Rad). Number of experiments: 9.
Animals and Groups
Adult male Sprague-Dawley rats weighing 270–310 g were bred
at and obtained from the Laboratory Animal Center of the
Chongqing Medical University. All rats were housed in a colony
room with food and water available before the operation under
optimal conditions (12/12 h light/dark cycle with humidity
60 ± 5%, 22 ± 3◦C). Experimental animals were randomly
allocated to the following groups: (1) sham group (Sham);
(2) MCAO group (MCAO): underwent MCAO; (3) scramble
group (Scramble): treated with scramble of Prdx6 siRNA and
subjected to MCAO; (4) Prdx6 siRNA group (Prdx6 siRNA):
treated with Prdx6 siRNA and subjected to MCAO; and
(5) Prdx6 siRNA + MJ33 group (Prdx6 siRNA + MJ33): treated
with MJ33 (0.5 µmol/kg, by tail vein, at 24 h before MCAO) and
Prdx6-siRNA and subjected to MCAO.
Administration of Prdx6 siRNA
Prdx6 siRNA (sense primer 5-CUUCCACGAUUUCCUAGG
ATT-3 and antisense primer 5-UCCUAGGAAAUCGUGGAA
GTT-3) were designed and chemically synthesized by
GenePharma Corporation, Shanghai, China. A scramble of
Prdx6 siRNA, which has the same nucleotide composition of the
target gene siRNA with no sequence homology to any known rat
genes, was used as the control. Rats were anesthetized, and 6 µL
FIGURE 1 | The efficiency of phospholipase A2 of peroxiredoxin 6 (Prdx6-iPLA2) siRNA. Effects of siRNA on mRNA (A) and protein expression (B) of Prdx6.
(C) An independent phospholipase A2 (iPLA2) enzyme-linked immunosorbent assay (ELISA) kit was used to measure the PLA2 activity in microglia. (D) Both
Prdx6-iPLA2 siRNA and 1-hexadecyl-3-(trifluoroethgl)-sn-glycerol-2 phosphomethanol (MJ33) had no effect on GSH activity. Values are expressed as mean ± SEM
of three independent experiments, ∗p < 0.05 vs. Control; ∗∗p < 0.01 vs. Control; #p < 0.05 vs. Scramble, ##p < 0.01 vs. Scramble.
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siRNA was injected into the left lateral cerebral ventricle, siRNA
was slowly injected into the left lateral ventricle over a 5 min
duration using a Hamilton microsyringe with the coordinates of
1.0 mm posterior to the bregma, 2.0 mm lateral to the midline,
and 3.5 mm ventral to the surface of the skull under the guidance
of a stereotaxic instrument. After injection, the needle was held
in place for 5 min and then removed slowly.
Middle Cerebral Artery Occlusion Model
TheMCAO technique was used to induce transient focal cerebral
ischemia according to our previously published methods (Chen
et al., 2016; Li et al., 2016). Briefly, ischemia was produced
by advancing the tip of a rounded 0.32 mm monofilament
nylon suture (Beijing Sunbio Biotech Co. Ltd, Beijing, China)
into the left internal carotid artery through the common
carotid artery stump and gently advanced to occlude the
MCA. After 1 h of occlusion, the thread was withdrawn to
restore blood flow. Sham-operated animals received the same
procedure, with the left common carotid artery isolated, but
not occluded. Rats that did not show neurological deficits after
reperfusion (neurological score <2) were excluded from the
study, as were animals that died after ischemia induction. Rats
that showed neurological deficits immediately after reperfusion
(neurological score =2) but were found to be experiencing
skull-base or subarachnoid hemorrhage were also excluded from
the study.
FIGURE 2 | Effects of Prdx6-iPLA2 on neuron viability and cell damage
in response to oxygen glucose deprivation and regeneration (OGD/R).
(A) Neuron viability was measured by MTS assay. (B) Neuron damage was
measured by Lactate dehydrogenase (LDH) assay. Number of experiments: 9.
Values are mean ± SEM, ∗∗p < 0.01 vs. Control; #p < 0.05 vs. Scramble.
Evaluation of Neurological Deficit Score
Neurological deficit scores were assessed by an examiner blinded
to the experimental groups after 24 h of reperfusion. The deficits
were scored on a modified scoring system developed by Longa
et al. (1989) as follows: 0, no neurological deficits; 1, failure
to extend right forepaw fully; 2, circling to right; 3, falling to
right; and 4, does not walk spontaneously and has depressed
levels of consciousness. The higher the neurological deficit score,
the more severe the impairment of motor motion injury. Nine
animals were taken for each group. Brains from these rats
were analyzed for water content, infarct volume, ELISA analysis,
Western blot, and real-time qPCR.
Measurement of Brain Edema
Brain water content was measured using the standard wet-dry
method. The brains were rapidly removed and dissected into the
ipsilateral and contralateral hemispheres. The two hemispheres
were immediately weighed on an electronic balance to obtain the
wet weight and then heated in an oven at 100◦C for 48 h to obtain
the dry weight. Brain water content was calculated using the
following formula: brain water content (%) = (1− dry weight/wet
weight)× 100%.
FIGURE 3 | Effect of Prdx6-iPLA2 on the release of interleukin1β
(IL-1β), interleukin-17 (IL-17) and interleukin-23 (IL-23) in culture
medium in response to OGD/R (A–C). Number of experiments: 9. Values
are mean ± SEM, ∗p < 0.05 vs. Control; ∗∗p < 0.01 vs. Control;
#p < 0.05 vs. Scramble; ##p < 0.01 vs. Scramble.
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FIGURE 4 | Effect of Prdx6-iPLA2 on Toll-like receptor 2 (TLR2) and TLR4 expression in microglia in response to OGD/R. TLR2 and TLR4 were activated
during OGD/R exposure. Prdx6-iPLA2 siRNA or MJ33 treatment could inhibit TLR2 and TLR4 mRNA (A,B) and protein expression (C–E). Results are expressed as
the mean ± SEM of three independent experiments. ∗∗p < 0.01 vs. Control; #p < 0.05 vs. Scramble; ##p < 0.01 vs. Scramble.
Infarct Volume Analysis
The brain infarct area was evaluated using 2,3,5-
triphenyltetrazolium chloride (TTC) staining. TTC was
converted to red formazan product in the presence of a
functioning mitochondrial electron transport chain. The
infarct tissue areas of all coronal sections of each brain
were measured using Image-Pro Plus software as described
previously. The corrected volume was calculated according
to the formula: percentage of infarct volume (%) = [total
infarct volume − (left hemisphere volume − right hemisphere
volume)]/right hemisphere volume× 100% (Chen et al., 2012).
ELISA Assay for IL-1β, IL-17 and IL-23
To investigate the level of interleukin cytokine expression, a rat
IL-1β, interleukin-17 (IL-17) and interleukin-23 (IL-23) enzyme-
linked immunosorbent assay (ELISA) kit (Nanjing Jiancheng;
R&D Systems) was used according to the manufacturer’s
instructions. Absorbance was determined at 450 nm by
spectrometry.
Real-Time qPCR Analysis
For real-time RT-PCR, the total RNA from primary cultured
microglia cells and brain tissues of rats was extracted and
purified as previously reported (Yamada et al., 2002). Then
the RNA was converted to complementary DNA (cDNA) by
reverse transcription (Bio-Rad). Then, cDNA was performed by
a PrimeScriptTM RT regent kit (TaKaRa Biotechnology, Dalian).
The primer sequences (Sangon Biotech, Shanghai, China) were
as follows: Prdx6 (forward primer, 5′-ACAgCCCgTgTggTA
TTCAT-3′, reverse primer, 5′-CTCTCTCCCTTCTTCCAGTC
AA-3′), inducible nitric oxide synthase (iNOS; F, 5′-gTgCTAA
TgCggAAggTCAT-3′, R, 5′-gAAggCgTAgCTgAACAAgg-3′),
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FIGURE 5 | Effect of Prdx6-iPLA2 on nuclear factor-kappa B (NF-κB), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)
expression in microglia in response to OGD/R. (A–C) mRNA levels analyzed by quantitative RT-PCR. Representative Western blot bands and semi-quantitative
analyses of NF-κB (D,E), iNOS (D,F) and COX-2 (D,G) expression in astrocytes under OGD/R. Results are expressed as mean ± SEM of three independent
experiments. ∗p < 0.05 vs. Control; ∗∗p < 0.01 vs. Control; #p < 0.05 vs. Scramble; ##p < 0.01 vs. Scramble.
TLR2 (F, 5′-gAgTCTgCTgTgCCCTTCTC-3′, R, 5′-gCTTTCTT
gggCTTCCTCTT-3′), TLR4 (F, 5′-TggCATCATCTTCATTgTC
C-3′, R, 5′-CAgAgCATTgTCCTCCCACT-3′), cyclooxygen
ase-2 (COX-2; F, 5′-GTTGCTGGGGGAAGGAATGT-3, R, 5′-A
GAAGCGTTTGCGGTACTCA-3′), nuclear factor-kappa
B (NF-κB; F, 5′-ACGACGATCCTTTCGGAACT-3′, R, 5′-
TGTTGACAGTGGTATATCTGTTGAA-3′), β-actin (F, 5′-
CACCCGCGAGTACAACCTTC-3′, R, 5′-CCCATACCCACCA
TCACACC-3′). The data were analyzed using a Bio-Rad
CFX96 Connect Real-Time system. The mRNA levels were
standardized to β-actin, and the values were expressed as the fold
change of the threshold cycle value for the control by the 2−11Ct
method. Three independent experiments were performed.
Western Blot Analysis
Proteins were obtained and homogenized in the RIPA
buffer. Equivalent amounts of protein (30 µg) were loaded
and separated by 10% SDS-PAGE gels, then transferred to
polyvinylidene difluoride (PVDF) membranes (0.45 mm). The
membranes were washed in Tris-buffered saline containing
0.05% Tween-20 (TBST) followed by blocking for 1 h using
5% nonfat milk in TBST at room temperature, then incubated
at 4◦C overnight with the following primary antibodies:
monoclonaln antibody to Prdx6 (1:1000; ab133348, Abcam,
Cambridge, MA, USA), rabbit polyclonal antibody to TLR2 and
TLR4 (1:400, BA1716/BA1717, Boster Biological Technology,
China), rabbit polyclonal antibody to NF-κB (1:1000; sc-109,
Santacruz, CA, USA), rabbit monoclonal antibody to iNOS
(1:500, bs0162R, Bioss, China), rabbit monoclonal antibody to
COX-2 (1:500, 55070-1-AP, Proteintech, China,) and mouse
monoclonal antibody to β-actin (1:10,000, D110007-0100,
Songon Biotech, China). The next day, the blots were washed
and incubated for 1 h with respective HRP-conjugated secondary
antibodies (ZSGB-BIO, Beijing, China; dilution 1:3000) at room
temperature. Finally, the protein was visualized using the ECL
kit (Millipore, Temecula, CA, USA). The results were quantified
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using Quantity One 1-D analysis software, and β-actin was used
as the internal control. Three independent experiments were
taken.
Statistical Analysis
All data were expressed as mean ± SEM and analyzed using
Statistical Package for Social Sciences (SPSS) 16.0 software.
One-way analysis of variance (ANOVA) were performed,
followed by post hoc tests with the least significant difference
(LSD; under variance homogeneity). Moreover, Kruskal-Wallis
and Welch’s ANOVA were both used for heteoscedastic
data. A value of P < 0.05 was considered statistically
significant.
RESULTS
The Efficiency of Prdx6-iPLA2 siRNA
As mentioned in "Materials and Methods" Section, we used an
siRNA and, following functional recovery, performed mediated
knockdown of Prdx6-iPLA2 activity. Previous research has
shown that Prdx6 siRNA can reduce both iPLA2 and GSH
activity (Jo et al., 2013), In order to detect the siRNA
efficiency, we added a Prdx6 siRNA group as a control. First,
qPCR and Western blotting were used to ascertain whether
the Prdx6 mRNA and protein levels were reduced in the
microglia (three independent experiments were performed).
Figures 1A,B show that considerable reduction in Prdx6 was
observed in the Prdx6 siRNA group (P < 0.05). No statistical
difference in Prdx6 expression was observed between the
OGD/R group, Scramble group, Prdx6-iPLA2 siRNA group
and MJ33 group. Next, an iPLA2 ELISA kit was used to
measure the iPLA2 activity in microglia (Figure 1C). Compared
with the Sham group, the iPLA2 activity was increased in the
OGD/R group and Scramble group. Treatment with Prdx6-
iPLA2 activity siRNA or iPLA2 inhibitors (MJ33) resulted in
a significant decrease of iPLA2 activity compared with the
Scramble group. Additionally, we detected GSH peroxidase
activity (Figure 1D). Prdx 6 siRNA suppressed GSH activity.
Both Prdx6-iPLA2 siRNA and MJ33 had no effect on GSH
peroxidase activity (P > 0.05). All of these results suggest that
our methods had interference efficiency of Prdx6-iPLA2 activity
in microglial cells.
Effect of Prdx6-iPLA2 Activity on Neuron
Viability and Damage in Response to
OGD/R
The MTS assay was used to measure the effect of Prdx6-
iPLA2 activity on neuron viability after OGD/R exposure
(Figure 2A). Cell viability was significantly decreased in the
OGD/R group compared with the untreated group (P < 0.01).
The total number of viable neurons increased to 65 ± 6.4%
and 58.8 ± 7% in the Prdx6-iPLA2 siRNA and MJ33 groups,
respectively (Figure 2A). In parallel, the release of LDH in
neurons was measured (Figure 2B). The siRNA of Prdx6-
iPLA2 could decrease the LDH release from neurons compared
with the control group (n = 9, P < 0.05). MJ33 is a fluorinated
phospholipid analog that shows relatively tight binding to Prdx6
(Manevich and Fisher, 2005). MJ33 treatment had similar results.
These results suggest that the Prdx6-iPLA2 siRNA could reduce
neuron damage after OGD/R.
Effect of Prdx6-iPLA2 Activity on the
Release of IL-1β, IL-17 and IL-23 in Culture
Medium in Response to OGD/R
In order to measure the effects of Prdx6-iPLA2 activity
on the expression of inflammatory mediators, ELISA
assays was performed. As shown in Figures 3A–C, Prdx6-
iPLA2 siRNA significantly decreased the levels of IL-1β, IL-17
and IL-23–35.25± 4.2 (pg/ml; Figure 3A, n = 9, P < 0.05),
FIGURE 6 | Effect of Prdx6-siRNA and MJ33 on the expression of
Prdx6 and iPLA2 activity following middle cerebral artery occlusion
(MCAO). qPCR (A) and Western blot (B) results showed that the expression
of Prdx6 was reduced in the Prdx6-siRNA group. ELISA (C) results also
showed that a significant decrease of iPLA2 activity was found in the Prdx6 +
MJ33 group. Results are expressed as mean ± SEM of three independent
experiments. &p < 0.01 vs. Sham; ∗∗p < 0.01 vs. MCAO; ##p < 0.01 vs.
Prdx6-siRNA.
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53 ± 4.5 (pg/ml; Figure 3B, P < 0.01) and 49 ± 5.4 (pg/ml;
Figure 3C, n = 9, P < 0.01), respectively, compared to the
Scramble group. MJ33 treatment also decreased these mediators.
These results suggest that Prdx6-iPLA2 activity may affect the
release of some inflammatory cytokines.
Effect of Prdx6-iPLA2 Activity on TLR2 and
TLR4 Signaling Pathway in Response to
OGD/R
We next investigated whether the TLR2/4 signaling pathway
was involved in the Prdx6-iPLA2-mediated activation of
inflammatory mediators. After OGD 6 h/R 24 h, microglial
cells were harvested for Western blot analysis. As shown in
Figure 4, the Scramble group showed no changes in expression
levels of TLR2 or TLR4, while Prdx6-iPLA2 siRNA markedly
reduced both the mRNA and protein levels of TLR2 and TLR4,
relative to the Scramble group. Similar results were obtained with
MJ33 treatment.
Effect of Prdx6-iPLA2 Activity on the
Expression of NF-κB, iNOS and COX- 2 in
Response to OGD/R
The expression of molecules involved in the intracellular
TLR2 and TLR4 signaling pathways was detected. The
mRNA expression levels of NF-κB, iNOS and COX-2 were
decreased by Prdx6-iPLA2 siRNA treatment (Figures 5A–C).
In Figures 5D–G, the Western blot results and quantification
showed that the protein expression levels of NF-κB, iNOS
and COX-2 in the Prdx6-iPLA2 siRNA group decreased
by 50.27% (P < 0.01), 66.67% (P < 0.05) and 58.44%
FIGURE 7 | Effect of Prdx6 siRNA and MJ33 on cerebral infarct volume, neurologic deficit scores and brain water content following transient MCAO.
(A) Representative images of TTC-stained sections 24 h after MCAO. (B) Prdx6 siRNA significantly increased cerebral infarct volume compared with the MCAO
group. Combine treatment with Prdx6 siRNA and MJ33 attenuated the injury. Neurological function (C) and brain water content (D) were tested after 24 h of MCAO
in rats. Values are mean ± SEM of nine animals in each group. &p < 0.01 vs. Sham; ∗∗p < 0.01 vs. Scramble; #p < 0.05, vs. Prdx6 siRNA; ##p < 0.01 vs.
Prdx6 siRNA.
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(P < 0.01), respectively, relative to the Scramble group.
Consistent with previous studies, blocking Prdx6 iPLA2 activity
by MJ33 significantly decreased the injury associated with
inflammation (Kuang et al., 2014).
Effect of Prdx6 siRNA and MJ33 on the
Expression of Prdx6 and iPLA2 Activity
Following MCAO
We next investigated the role of iPLA2 activity of Prdx6 in
transient cerebral ischemia and the potential mechanism
underlying the observations.Western blotting and real-time PCR
were performed to measure the expression of Prdx6 at mRNA
and protein levels (Figures 6A,B). Then, the iPLA2 activity
of Prdx6 was detected by ELISA (Figure 6C). Significant
decreases in Prdx6 mRNA and proteins levels were observed
in the Prdx6 siRNA group. Although additional treatment
with MJ33 did not significantly influence the expression
of Prdx6 stimulated by Prdx6 siRNA (Figures 6A,B,
P > 0.05), additional injection with MJ33 resulted in
a significant decrease of iPLA2 activity (Figure 6C,
P < 0.01).
Effect of Prdx6 siRNA and MJ33 on
Cerebral Infarct Volume, Neurologic Deficit
Scores and Brain Water Content Following
MCAO
As shown in Figure 7, compared with the MCAO group,
Prdx6 siRNA was associated with significantly aggravated infarct
volume (Figures 7A,B, P < 0.01). However, this increase was
mitigated by additional treatment of the rat with MJ33, an
inhibitor of iPLA2 activity. Compared with the Prdx6 siRNA
group, similar attenuation was observed in the neurological
deficit analysis (Figure 7C, n = 9, P < 0.01) and brain water
content (Figure 7D, n = 9, P < 0.01) in the Prdx6 siRNA +
MJ33 group.
Effect of Prdx6 siRNA and MJ33 on the
Producion of IL-1β, IL-17 and IL-23 in
Cortex Following MCAO
To detect the production of IL-1β, IL-17 and IL-23 in brain
ischemia/reperfusion, ELISA were performed. As shown in
Figure 8, Prdx6 siRNA caused increased release and expression
of IL-1β(A), IL-17 (B) and IL-23 (C). However, additional
treatment with MJ33 significantly blocked the increase in these
inflammatory cytokines in rats stimulated by Prdx6 siRNA
treatment.
Effect of Prdx6 siRNA and MJ33 on
TLR2 and TLR4 Expression in the Cortex
Following MCAO
To determine the underlying molecular effects of
iPLA2 activation in vivo, rat cortical tissue from MCA
regions was harvested and analyzed by real-time PCR and
Western blotting. As shown in Figure 9, the expression of
TLR2 and TLR4 in cortex was significantly increased after
FIGURE 8 | The influence of Prdx6-siRNA and MJ33 on the production
of inflammatory cytokines IL-1β, IL-17 and IL-23. The ELISA results
indicated that IL-1β (A), IL-17 (B) and IL-23 (C) were upregulated by
Prdx6 siRNA after MCAO. These increase were attenuated by additional
treatment of rats with MJ33. The results are expressed as the mean ± SEM of
nine animals in each group. &p < 0.01 vs. Sham; ∗∗p < 0.01 vs. Scramble;
#p < 0.05, vs. Prdx6 siRNA.
MCAO. Prdx6 siRNA significantly increased the expression of
TLR2 and TLR4 in comparison to the Sham group. Compared
with the Prdx6 siRNA group, both the mRNA (Figures 9A,B)
and protein levels (Figures 9C–E) of TLR2 and TLR4 were
significantly decreased in the same brain areas by combined
exposure to Prdx6 siRNA and MJ33.
Effect of Prdx6 siRNA and MJ33 on the
Expression of NF-κB, iNOS and COX- 2 in
the Cortex Following MCAO
We next investigated changes in the mRNA and protein
expression of molecules involved in the intracellular TLR2 and
TLR4 signaling pathways. MCAO caused increased protein
expression of NF-κB, iNOS and COX-2 in the cortex
compared with the Sham group (Figures 10A–C). Prdx6 siRNA
upregulated the expression of these proteins compared with
the control groups (Figures 10D–G). Compared with the
Prdx6 siRNA group, combined exposure to Prdx6 siRNA and
MJ33 significantly downregulated the mRNA and protein
expression of NF-κB, iNOS and COX-2.
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FIGURE 9 | Expression of TLR2 and TLR4 in response to Prdx6 siRNA and MJ33. Real-time PCR showed that TLR2 (A) and TLR4 (B) expression increased
after MCAO or giving Prdx6-siRNA. Combined treatment with Prdx6-siRNA and MJ33 downregulated TLR2 and TLR4 levels. Representative Western blot (C) and
semi-quantitative analyses of the levels of TLR2 (D) and TLR4 (E) in the cortex after MCAO. Results are expressed as the mean ± SEM of three independent
experiments. &p < 0.01 vs. Sham; ∗∗p < 0.01 vs. Scramble; #p < 0.05, vs. Prdx6 siRNA; ##p < 0.01 vs. Prdx6 siRNA.
DISCUSSION
In the present study, we explored the function of Prdx6-
iPLA2 in cerebral ischemia/reperfusion injury in both OGD/R
microglia/neuron co-culture and MCAO models. In the
co-culture system, we employed siRNA knockdown and
inhibition of Prdx6-iPLA2 activity in the microglia; both
resulted in increased neuron survival. We further found that
Prdx6-iPLA2 was associated with the secretion of neurotoxic
inflammatory mediators (IL-1β, IL-17 and IL-23) and the
levels of the TLR2/4 signaling pathway in microglial cells.
in vivo, consistent with previous reports, the knockdown
of Prdx6 by antisense (Prdx6-siRNA) revealed that loss of
Prdx6 contributed to increased cerebral infarct volume and
poor functional outcomes (Chhunchha et al., 2013; Pan et al.,
2014). However, combined treatment with Prdx6 siRNA and
Prdx6-iPLA2 inhibitor MJ33 showed a greater diminution in
neurologic deficits, cerebral infarction, brain water content and
inflammatory molecules than Prdx6-siRNA treatment alone.
Thus, the iPLA2 activity of Prdx6 may play a critical role
in cerebral ischemia/reperfusion injury, which might target
TLR2/4 inflammatory cascades.
Emerging evidence suggests that macrophage/microglia-
induced neuroinflammation often precedes and triggers
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FIGURE 10 | Expression of NF-κB, iNOS and COX-2 in response to Prdx6 siRNA and MJ33. Real-time PCR results, representative Western blot bands, and
semi-quantitative analyses of NF-κB (A,D,E), iNOS (B,D,F) and COX-2 (C,D,G) in the cortex following MCAO. Results are expressed as the mean ± SEM of three
independent experiments. &p < 0.01 vs. Sham; ∗∗p < 0.01 vs. Scramble; #p < 0.05, vs. Prdx6 siRNA; ##p < 0.01 vs. Prdx6 siRNA.
neuronal death in cerebral ischemic disorders. In comparison to
monolayer cultures, we established a Transwell co-culture model
to better explore microglia-neuron crosstalk. In this system, the
two kinds of cells share the same medium and interact through
diffusible molecules only. As reported by others, we adopted the
Neurobasal medium to meet higher nutrition requirements for
neurons (Xing et al., 2013). Before OGD/R treatment, microglia
and neurons were co-cultured 24 h for utmost microglial
activation. The factors for the harmful inflammatory secreted
by microglia have not been clearly defined, but activation of
receptors of the innate immune system, including TLR2, TLR4
and their downstream inflammatory cytokines (NF-κB, COX-2
and NOS2) has emerged as a key step in the signaling cascade (Tu
et al., 2011; Wang et al., 2013; Lv et al., 2016). Specific molecules
blocking TLR2/4 signaling or its endogenous danger-associated
molecular patterns (DAMPs) may be a novel therapeutic strategy
for post-stroke neuronal inflammation and brain injury (Tu
et al., 2010; Kuang et al., 2014; Yu et al., 2015).
Prdx6 is a bifunctional enzyme that harbors iPLA2 (Ca[2+]-
independent phospholipase A2) activity in addition to its
GSH peroxidase function. Prdx6-iPLA2, rather than other
iPLA2 enzymes, was found to be harmful to the cells
(Ellison et al., 2012; Krishnaiah et al., 2013). iPLA2 activity
of Prdx6 involved in the TNF-induced apoptosis and the
proinflammatory response (Kim et al., 2011). In the pulmonary
endothelium and alveolar macrophages, Prdx6-iPLA2 activity
modulates NOX2 activation via lysophosphatidic acid receptor
signaling (Vázquez-Medina et al., 2016). In this study, our
focus was the function of Prdx6-iPLA2 activity in the ischemic
brain, which is especially at risk for microglia-mediated
neuroinflammatory injury associated with TLR2/4 activation.
Single-point deficient mutation by lentivirus gene
transduction in primary cerebral cells seemed difficult under
our experimental conditions. Here, we described an siRNA
and, following functional recovery, performed a mediated
knockdown of Prdx6-iPLA2 activity. Finally, we detected
successful iPLA2 siRNA with iPLA2 assays. The Prdx6-
iPLA2 siRNA showed the same results as MJ33: both had no
effect on GSH peroxidase activity (Fisher et al., 1992; Benipal
et al., 2015). Previous reports have shown that the iPLA2 activity
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of Prdx6 is involved in the proinflammatory response (Kim
et al., 2011; Shichita et al., 2012a,b). In our study, we found
that knockdown of Prdx6-iPLA2 in microglia significantly
moderated OGD/R injury to co-culture neurons, which may be
associated with decreases in both the RNA and protein levels
of TLR2/4 expression. Like other Prdx proteins, Prdx6 proteins
have an active region of TLR2/4 activation and are extracellularly
released over 12 h after stroke onset, which coincides with
the timing of leukocyte infiltration (Shichita et al., 2012a,b).
iPLA2 activity of Prdx6 induced the release of arachidonic
acid (AA), which is involved in the inflammatory response
(Kim et al., 2011). In addition, AA’s upregulation of TLR4 and
downregulation of PPARγ may be associated with acute
pancreatitis (Mateu et al., 2015). All of these findings suggest
that TLR signaling is effected directly or indirectly by Prdx6-
iPLA2 activity. Recently, two opposing functions of Prdx6 were
shown in brain cells: first, intracellular Prdx6 is thought to be
neuroprotective; second, when Prdx6 is released from necrotic
cells, it functions as a strong TLR2 and TLR4 stimulator (Shichita
et al., 2012a,b; Kuang et al., 2014). It is interesting to note that
Prdx6-iPLA2 may be associated with the same inflammation
pathway in our present experiment. Because the stimulation of
cells may result in Prdx6 binding to the cell membrane, that may
activate its iPLA2 activity (Ambruso et al., 2012; Ellison et al.,
2012; Krishnaiah et al., 2013). This suggests that there may be
a relationship between the Prdx6-iPLA2 and its extracellular
danger signal, which requires further study.
In conclusion, our study demonstrated that the iPLA2 of
Prdx6 plays important physiological roles in cerebral
inflammatory injury both in vitro and in vivo. siRNA of Prdx6-
iPLA2 was accompanied by reduced expression of inflammation
cytokines IL-1β, IL-17 and IL-23.The iPLA2 activity of
Prdx6 may contribute to neuroinflammation by regulating
TLR2/4, leading to the formation of neurotoxic levels of NF-κB,
iNOS and COX-2. Our findings provide new insight into Prdx6-
iPLA2 function in the brain. Inhibition of Prdx6 iPLA2 activity
by gene therapy and/or pharmacological means may constitute
a promising new therapeutic approach to the treatment of
stroke.
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